中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2015年
5期
420-422
,共3页
脑梗死%阿托伐他汀钙%血脂%超敏C反应蛋白
腦梗死%阿託伐他汀鈣%血脂%超敏C反應蛋白
뇌경사%아탁벌타정개%혈지%초민C반응단백
Cerebral infarction%Atorvastatin%Blood lipid%High-sensitivity C-reactive protein
目的 探讨阿托伐他汀钙对急性脑梗死患者血脂和血清超敏C反应蛋白(hs-CRP)的影响.方法 将140例急性脑梗死患者应用随机数字表分为对照组和观察组,每组70例.所有患者均给予常规治疗,对照组在常规治疗基础上加用辛伐他汀,观察组在常规治疗基础上加用阿托伐他汀钙.疗程均为4周.比较治疗前后两组患者血脂变化以及治疗前与治疗1周和4周时血清hs-CRP的变化.结果 对照组治疗前、后总胆固醇(TC)分别为(6.4±1.6)、(6.4±1.6) mmol/L,甘油三酯(TG)分别为(3.3±0.6)、(2.2±0.5) mmol/L,低密度脂蛋白胆固醇(LDL-C)分别为(4.7±0.8)、(3.3±0.6)mmol/L,差异均有统计学意义(t=7.364、P=0.028,t=5.872、P=0.042,t=5.692、P=0.035);观察组治疗前、后TC、TG、LDL-C分别为(6.4±1.4)、(3.5±0.6) mmol/L,(3.2±0.8)、(1.8±0.5)mmol/L,(4.6±0.6)、(2.4±0.5) mmol/L,差异均有统计学意义(t=8.657、P=0.015,t=6.264、P=0.029,t=6.674、P=0.043),且观察组下降更为明显(与对照组治疗后相比t值分别为4.264、4.827和4.874,P均＜0.05);对照组治疗前、后高密度脂蛋白胆固醇(HDL-C)分别为(1.3±0.4)、(1.6±0.7)mmol/L,观察组分别为(1.2±0.5)、(2.4±0.5) mmol/L,差异均有统计学意义(t=5.976、P=0.039,t=6.743、P=0.031),且观察组上升更为明显(与对照组治疗后相比t=5.363、P＜0.05).治疗后两组患者血清hs-CRP水平均呈下降趋势,与治疗前相比差异有统计学意义,且观察组患者下降更为明显(处理主效应和时间主效应的F值分别为24.565和15.675,P均＜0.05).结论 阿托伐他汀钙可有效降低急性脑梗死患者的血脂和血清hs-CRP水平,从而降低脑血管病的发生率.
目的 探討阿託伐他汀鈣對急性腦梗死患者血脂和血清超敏C反應蛋白(hs-CRP)的影響.方法 將140例急性腦梗死患者應用隨機數字錶分為對照組和觀察組,每組70例.所有患者均給予常規治療,對照組在常規治療基礎上加用辛伐他汀,觀察組在常規治療基礎上加用阿託伐他汀鈣.療程均為4週.比較治療前後兩組患者血脂變化以及治療前與治療1週和4週時血清hs-CRP的變化.結果 對照組治療前、後總膽固醇(TC)分彆為(6.4±1.6)、(6.4±1.6) mmol/L,甘油三酯(TG)分彆為(3.3±0.6)、(2.2±0.5) mmol/L,低密度脂蛋白膽固醇(LDL-C)分彆為(4.7±0.8)、(3.3±0.6)mmol/L,差異均有統計學意義(t=7.364、P=0.028,t=5.872、P=0.042,t=5.692、P=0.035);觀察組治療前、後TC、TG、LDL-C分彆為(6.4±1.4)、(3.5±0.6) mmol/L,(3.2±0.8)、(1.8±0.5)mmol/L,(4.6±0.6)、(2.4±0.5) mmol/L,差異均有統計學意義(t=8.657、P=0.015,t=6.264、P=0.029,t=6.674、P=0.043),且觀察組下降更為明顯(與對照組治療後相比t值分彆為4.264、4.827和4.874,P均＜0.05);對照組治療前、後高密度脂蛋白膽固醇(HDL-C)分彆為(1.3±0.4)、(1.6±0.7)mmol/L,觀察組分彆為(1.2±0.5)、(2.4±0.5) mmol/L,差異均有統計學意義(t=5.976、P=0.039,t=6.743、P=0.031),且觀察組上升更為明顯(與對照組治療後相比t=5.363、P＜0.05).治療後兩組患者血清hs-CRP水平均呈下降趨勢,與治療前相比差異有統計學意義,且觀察組患者下降更為明顯(處理主效應和時間主效應的F值分彆為24.565和15.675,P均＜0.05).結論 阿託伐他汀鈣可有效降低急性腦梗死患者的血脂和血清hs-CRP水平,從而降低腦血管病的髮生率.
목적 탐토아탁벌타정개대급성뇌경사환자혈지화혈청초민C반응단백(hs-CRP)적영향.방법 장140례급성뇌경사환자응용수궤수자표분위대조조화관찰조,매조70례.소유환자균급여상규치료,대조조재상규치료기출상가용신벌타정,관찰조재상규치료기출상가용아탁벌타정개.료정균위4주.비교치료전후량조환자혈지변화이급치료전여치료1주화4주시혈청hs-CRP적변화.결과 대조조치료전、후총담고순(TC)분별위(6.4±1.6)、(6.4±1.6) mmol/L,감유삼지(TG)분별위(3.3±0.6)、(2.2±0.5) mmol/L,저밀도지단백담고순(LDL-C)분별위(4.7±0.8)、(3.3±0.6)mmol/L,차이균유통계학의의(t=7.364、P=0.028,t=5.872、P=0.042,t=5.692、P=0.035);관찰조치료전、후TC、TG、LDL-C분별위(6.4±1.4)、(3.5±0.6) mmol/L,(3.2±0.8)、(1.8±0.5)mmol/L,(4.6±0.6)、(2.4±0.5) mmol/L,차이균유통계학의의(t=8.657、P=0.015,t=6.264、P=0.029,t=6.674、P=0.043),차관찰조하강경위명현(여대조조치료후상비t치분별위4.264、4.827화4.874,P균＜0.05);대조조치료전、후고밀도지단백담고순(HDL-C)분별위(1.3±0.4)、(1.6±0.7)mmol/L,관찰조분별위(1.2±0.5)、(2.4±0.5) mmol/L,차이균유통계학의의(t=5.976、P=0.039,t=6.743、P=0.031),차관찰조상승경위명현(여대조조치료후상비t=5.363、P＜0.05).치료후량조환자혈청hs-CRP수평균정하강추세,여치료전상비차이유통계학의의,차관찰조환자하강경위명현(처리주효응화시간주효응적F치분별위24.565화15.675,P균＜0.05).결론 아탁벌타정개가유효강저급성뇌경사환자적혈지화혈청hs-CRP수평,종이강저뇌혈관병적발생솔.
Objective To analyze influence of atorvastatin calcium on blood lipid and high-sensitivity C-reactive protein (hs-CRP) in patients with acute cerebral infarction.Methods One hundred and forty patients with acute cerebral infarction were randomly divided into the control group (n =70) and observation group(n =70).Patients in the control group were given simvastatin calcium,and in the observation group were given calcium beside control therapy scheme.The course was four weeks.The serum levels of blood lipid and hsCRP of before and one week and four weeks after treatment were measured and compared between the two groups.Results The total cholesterol(TC),glycerin trilaurate(TG) level and low density lipoprotein cholesterol (LDL-C) in control group before and after treatment were (6.4± 1.6) mmol/L and (6.4± 1.6) mmol/L,(3.3±0.6) mmol/L and (2.2±0.5) mmol/L,(4.7±0.8) mmol/L and (3.3±0.6) mmol/L,and the difference was significant (t=7.364,5.872,5.692;P=0.028,0.042,0.035).The TC,TG levels,LDL-C in observation group before and after treatment were (6.4±1.4) mmol/L and (3.5±0.6) mmol/L,(3.2±0.8) mmol/L and (1.8±0.5) mmol/L,(4.6±0.6) mmol/L and (2.4±0.5) mmol/L,and the differences were significant (t =8.657,6.264,6.674;P =0.015,0.029,0.043).Meanwhile,observation group decreased more significantly (t =4.264,4.827,4.874;P＜0.05).The HDL-C in control group before and after treatment were (1.3±0.4) mmol/L and (1.6± 0.7) mmol/L,in observation group were (1.2 ± 0.5) mmol/L and (2.4 ± 0.5) mmol/L,and the differences were significant (t =5.976,6.743;P =0.039,0.031).Meanwhile,observation group increased more significantly(t =5.363,P＜ 0.05).The hs-CRP of all groups significantly reduced after treatment,and the differences were statistically significant,and the degree of decline was more significant in observation group (treatment effects and time effects of the F values were 24.565 and 15.675,P ＜ 0.05).Conclusion Atorvastatin calcium can effectively reduce the blood lipid and hs-CRP of patients with acute cerebral infarction and the incidence of cerebrovascular disease,and it is worth popularization and application.
